Key Highlights

  • Senti Biosciences (NASDAQ:SNTI) traded at USD 0.2253, up 28.67%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day was identified, so the move sits against a pending transaction.
  • In the first-quarter results of Thursday, May 14, 2026, the company reported a net loss of USD 4.2 million, helped by a USD 6.9 million lease-modification gain, and cash of USD 8.9 million at Tuesday, March 31, 2026.
  • The transaction announced on Wednesday, July 15, 2026 would transfer the Gene-Circuit pipeline, including SENTI-202, to a Celadon-controlled company, with a contingent value right of up to USD 60 million to stockholders.
  • Nasdaq notices of Thursday, August 27, 2026 cite a bid price below USD 1.00 and a stockholders' deficit of USD 3,401,000 at Tuesday, June 30, 2026. Pre-market trading is thin and prices can change.

The Pre-Market Move and Its Catalyst

Senti Biosciences (NASDAQ:SNTI), a clinical-stage cell and gene therapy company, traded at USD 0.2253 in pre-market trading on Tuesday, October 27, 2026, a gain of 28.67% in the pre-market snapshot. Simple arithmetic on those two figures implies a prior close of about USD 0.1751. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The rise appears consistent with thin liquidity in a share priced far below USD 1.00 and with trading around a pending transaction announced on Wednesday, July 15, 2026, under which affiliates of Celadon, the largest investor, would acquire the Gene-Circuit pipeline, while stockholders would receive a contingent value right tied to milestone payments of up to USD 60 million over seven years.

How the Latest Filings Frame the Move

The Form 8-K of Thursday, August 27, 2026 sets out the balance sheet constraints. Senti Biosciences (NASDAQ:SNTI) received a Nasdaq notice that its shares closed below USD 1.00 for 30 consecutive trading days, with a compliance period to Tuesday, February 23, 2027, and a second notice that stockholders' equity was a deficit of USD 3,401,000 at Tuesday, June 30, 2026, against a USD 2.5 million requirement. A preliminary proxy filed on Tuesday, July 21, 2026 proposes a reverse share split and the transaction approvals. An amendment of Tuesday, September 1, 2026 allowed a third tranche of USD 2.0 million of senior secured convertible notes. First-quarter cash was USD 8.9 million, against USD 16.4 million at year-end 2025, with operating cash use of USD 7.5 million.

Risks and What to Watch

The bull reading is that SENTI-202, which holds FDA RMAT designation and showed durable MRD-negative responses in a 22-patient Phase 1 acute myeloid leukaemia trial, carries a contingent value right of up to USD 60 million, while the company retains its Regulator Dial platform. The bear reading is that the right is payable only on regulatory and sales milestones, that stockholders face a possible reverse split and dilution from convertible notes, and that the stockholders' deficit places the Nasdaq listing at risk. Investors should watch the Nasdaq plan on stockholders' equity, which the company was due to submit by Sunday, October 11, 2026, the stockholder meeting on the transaction, for which no date was given in the filing, and the bid price deadline of Tuesday, February 23, 2027.

Where Things Stand

The answer is that Senti Biosciences (NASDAQ:SNTI) rose in pre-market trading on Tuesday, October 27, 2026 without a dated company announcement, and the move appears consistent with thin liquidity around a pending Celadon transaction rather than a change in fundamentals. The key number is USD 60 million, the maximum value of the contingent value right payable over seven years. The next catalysts are the stockholder vote on the transaction, for which the filing gives no date, and the bid price compliance deadline of Tuesday, February 23, 2027. Pre-market prices are snapshots and can change, and this is not investment advice.